Syngene has a full service genetic toxicology department to support the genotoxic potential characterization of compounds from screening to IND submission. Our scientific staff and state-of-the-art facilities provide the most current and comprehensive genetic toxicology studies as per OECD guidelines. We have been executing genetic toxicology studies since 2010 and have an able and experienced analytical and bioanalytical team, toxicologists and statisticians. In the last two years itself we have completed over 300 genetic toxicology studies for our partners.
toxicology is a key aspect of the discovery and predictive phase of product development. They can increasingly provide stand-alone data for specific endpoints without in vivo
confirmatory studies. Also, in vitro
methods developed are more predictive of the human response and have a quicker turnaround time. They act as the crossover points between drug discovery and drug development and are widely used for screening and ranking of chemicals by studying specific target to cell and tissue. In addition to the standard genotoxicity studies such as bacterial reverse mutation, micronucleus test and chromosomal aberration, we conduct in vitro
cytotoxicity assay using neutral red uptake method, which is used to screen the cytotoxic potential of compounds. Recently we have also included in vitro
phototoxicity test using Balb/c 3T3 method and in vitro
skin irritation using Reconstructed Human Epidermis, skin corrosion using Reconstructed human epidermis and eye irritation using Reconstructed Human Cornea-like Epithelium test method.